Pasithea Therapeutics Corp.
KTTA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | -14.7% |
| R&D Expenses | $7 | $8 | $3 | $0 |
| G&A Expenses | $7 | $0 | $0 | $0 |
| SG&A Expenses | $7 | $0 | $10 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $8 | $0 | $5 |
| Operating Expenses | $14 | $16 | $13 | $5 |
| Operating Income | -$14 | -$16 | -$13 | -$5 |
| % Margin | – | – | – | -29,925.7% |
| Other Income/Exp. Net | $0 | $0 | $1 | $2 |
| Pre-Tax Income | -$14 | -$16 | -$12 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14 | -$16 | -$14 | -$2 |
| % Margin | – | – | – | -14,430.5% |
| EPS | -12.69 | -12.65 | -10.34 | -1.89 |
| % Growth | -0.3% | -22.3% | -447.1% | – |
| EPS Diluted | -12.69 | -13.01 | -10.34 | -1.89 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$14 | -$15 | -$12 | -$5 |
| % Margin | – | – | – | -29,916.6% |